The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of March 2021. This month are four guidelines that impact upon primary care.
The Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing guideline has been published. It sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance.
The Atopic eczema in under 12s: diagnosis and management guideline has been updated. It covers diagnosing and managing atopic eczema in children under 12. The update links to the new guideline covering management of secondary bacterial infection of eczema.
The Asthma: diagnosis, monitoring and chronic asthma management guideline has been updated. It covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. The update highlights the importance of including advice in the personalised action plan on minimising indoor air pollution and reducing exposure to outdoor air pollution.
The Cannabis-based medicinal products guideline has been updated. It covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The update clarified recommendations for the use of unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - March 2021||CKS Updates - March 2021 »|